Merck, Inc.
A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT06811246
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06809569
- Locations
- 🇧🇪
Center for Clinical Pharmacology (CCP) (Site 0001), Leuven, Vlaams-Brabant, Belgium
A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT06797674
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc ( Site 0001), Daytona Beach, Florida, United States
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Conditions
- Breast NeoplasmsBreast Cancer
- Interventions
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 372
- Registration Number
- NCT06797635
- Locations
- 🇺🇸
Northwest Cancer Specialists (Compass Oncology) ( Site 8003), Tigard, Oregon, United States
🇺🇸Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings, Montana, United States
🇺🇸SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, United States
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
- Conditions
- Lung Neoplasm Malignant
- Interventions
- Biological: Pembrolizumab (neoadjuvant)Biological: Pembrolizumab (adjuvant)Drug: AntihistamineDrug: H2 receptor antagonistDrug: Steroid mouthwash (dexamethasone or equivalent)
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06788912
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Careggi ( Site 0173), Firenze, Toscana, Italy
🇺🇸MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States
🇵🇱Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150), Gdansk, Pomorskie, Poland
A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
- Conditions
- Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
- Interventions
- Drug: LNG/EE
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT06783192
- Locations
- 🇺🇸
QPS-MRA, LLC-Early Phase (Site 0001), South Miami, Florida, United States
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Conditions
- Small Cell Lung Cancer
- Interventions
- Biological: Ifinatamab Deruxtecan (I-DXd)
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 138
- Registration Number
- NCT06780137
- Locations
- 🇨🇱
Bradfordhill ( Site 2101), Santiago, Region M. De Santiago, Chile
🇺🇸Dana Farber Cancer Institute ( Site 1105), Boston, Massachusetts, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103), Hackensack, New Jersey, United States
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 209
- Registration Number
- NCT06780111
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Conditions
- Lung Neoplasm
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 144
- Registration Number
- NCT06780098
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 96
- Registration Number
- NCT06780085